Pipeline

UNMATCHED BREAKTHROUGH
COUR’s CNP-101 for celiac disease, partnered with Takeda, is the first therapy to induce antigen-specific immune tolerance in any autoimmune disease in humans.

VALIDATED PLATFORM WITH BROAD APPLICATIONS
COUR’s Nanoparticle Platform can be employed to induce disease-specific tolerance for the treatment of a myriad of autoimmune and allergic diseases by changing the antigen or allergen that is encapsulated within the nanoparticle.

COUR is advancing its pipeline of first-in-class therapies for immune-mediated disease.